
HUTCHMED (China) Limited
- Jurisdiction
Hong Kong SAR China - LEI
2138006X34YDQ6OBYE79 - ISIN
US44842L1035 (HCM )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€16.12 25.9% undervalued - Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. Read full profile
Fundamentals
- Net revenue
€537.53M - Gross margin
11.0% - EBIT
-€37.28M - EBIT margin
-6.9% - Net income
€32.18M - Net margin
6.0%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: July 31, 2023 (Q2 2023)